

# Follicular Lymphoma Treatment Market, 2012-2023

<https://marketpublishers.com/r/F6999F1C149EN.html>

Date: January 2018

Pages: 203

Price: US\$ 4,400.00 (Single User License)

ID: F6999F1C149EN

## Abstracts

Global Follicular Lymphoma Treatment Market: By Treatment Type (Chemotherapy, Targeted Therapy, Radiotherapy, Monoclonal Antibodies, Stem Cell Transplantation), By Route of Administration (Oral, Parenteral), By End-User (Hospitals, Oncology Centers, Academic Research Institutes) and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

### Market Outline: Follicular Lymphoma Treatment Market

Follicular lymphoma is the second most common indolent non-Hodgkin's lymphoma and it develops when the body makes abnormal B-lymphocytes in lymph nodes. The symptoms associated with follicular lymphoma include enlargement of lymph nodes in neck, abdomen, and groin, weight loss, difficulties in breathing, fatigue, and night sweats. Follicular lymphoma is diagnosed by biopsy, blood tests, and X-rays among others. Follicular lymphoma can be treated with chemotherapy, radiation therapy, targeted therapy, and stem cell transplant.

### Market Dynamics: Follicular Lymphoma Treatment Market

Rise in prevalence of follicular lymphoma, family history of blood disorders, increase in R&D activities for the innovation of newer drugs, and technological advancements in disease diagnosis are anticipated to fuel the follicular lymphoma treatment market. Moreover, promising pipeline products, innovation of newer therapies such as monoclonal antibodies, and government initiations for the cancer management are expected to boost the market over the forecast period. However, stringent regulatory policies for drug approval, the high cost of treatment, and adverse effects associated with the treatment are expected to hamper the growth of follicular lymphoma treatment market over the forecast years.

## Market Scope: Follicular Lymphoma Treatment Market

Follicular lymphoma treatment market is segmented on the basis of treatment type, route of administration, end user, and region

Based on the treatment type, the market is segmented into the following:

- Chemotherapy
  - Alkylating Agents
  - Nucleoside Analogues
  - Anthracycline Derivatives
  - Others
- Radiotherapy
- Monoclonal Antibodies
- Stem Cell Transplantation

Based on the route of administration, the market is segmented into the following:

- Oral
- Parenteral
- Others

Based on the end user, the market is segmented into the following:

- Hospitals
- Retail Pharmacies

Oncology Centers

Academic Research Institutes

Based on region, the market is segmented into the following:

North America

Europe

Asia Pacific

Latin America

Middle East and Africa

### Market Summary: Follicular Lymphoma Treatment Market

Follicular lymphoma treatment market is poised to grow at significant rate owing to increase in the R&D activities for the innovation newer therapies and drugs. Most of the international players are actively involved in the development of newer products. For instance, in December 2015, Novartis announced phase IIa study results of CTL019 used in the treatment of certain types of lymphoma including follicular lymphoma. Moreover, rising adoption of monoclonal antibodies for targeted therapies propels the follicular lymphoma treatment market. Furthermore, acquisitions and mergers, collaborations, product approvals, and product launchings are the strategies followed by the market players for gaining larger revenue share in follicular lymphoma treatment market. For instance, in February 2017, Health Canada approved Roche's Gazyva (Obinutuzumab) for patients with previously treated follicular lymphoma. In addition, in August 2017, Epizyme, Inc. and US Oncology Research are collaborated to identify the non-Hodgkin lymphoma patients with EZH2 mutations and eligible patients are directed to ongoing phase 2 clinical trial of Tazemetostast in diffuse large B-cell lymphoma and follicular lymphoma.

### Regional Analysis: Follicular Lymphoma Treatment Market

Geographically, global follicular lymphoma treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America follicular lymphoma treatment market is poised to grow at notable rate due to increase in the prevalence of follicular lymphoma (according to American Cancer Society, approximately 20% of follicular lymphoma cases observed among all types lymphoma patients), increase in R&D activities for the innovation of newer drugs, an increase in healthcare expenditure in the region. Europe follicular lymphoma treatment market is expected to grow significantly due to the adoption of newer therapies, sophisticated healthcare infrastructure, an increase in the prevalence of follicular lymphoma due to change in lifestyle in the region. Asia Pacific follicular lymphoma treatment market has a lucrative growth owing to the large patient pool, increase in awareness about lymphoma treatment, and government initiations for the prevention of cancer are expected to fuel the market in the region. Latin America follicular lymphoma treatment market expected to grow at moderate rate due to the expansion of business into the region by market players, adoption of newer drugs, and economic growth are bolster the market. Middle East and Africa follicular lymphoma treatment market have a growth attributed to rising in awareness about lymphoma treatment, increase in the prevalence of follicular lymphoma, and growing per capita income.

#### Competition Assessment: Follicular Lymphoma Treatment Market

Some of the players in the global follicular lymphoma treatment market include:

Hoffmann La Roche Ltd. (Switzerland)

Novartis AG (Switzerland)

GlaxoSmithKline plc (U.K.)

Merck & Co. Inc. (U.S.)

AbbVie, Inc. (U.S.)

Bayer AG (Germany)

Epizyme Inc. (U.S.)

Bristol Myers Squibb (U.S.)

Johnson and Johnson Services Inc. (U.S.)

Notable Market Developments: Follicular Lymphoma Treatment Market

In October 2017, U.S. Food and Drug Administration approved Bayer AG's Aliqopa (Copanlisib) for the treatment of follicular lymphoma

## Contents

### **1. EXECUTIVE SUMMARY**

### **2. GLOBAL FOLLICULAR LYMPHOMA TREATMENT MARKET INTRODUCTION**

2.1. Global Follicular Lymphoma Treatment Market – Taxonomy

2.2. Global Follicular Lymphoma Treatment Market –Definitions

2.2.1. Treatment Type

2.2.2. Route of Administration

2.2.3. End-User

### **3. GLOBAL FOLLICULAR LYMPHOMA TREATMENT MARKET DYNAMICS**

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Follicular Lymphoma Treatment Market Dynamics – Factors Impact Analysis

3.6. Global Follicular Lymphoma Treatment Market – Regulations

3.6.1. U.S.

3.6.2. Europe

3.6.3. Japan

3.7. Global Follicular Lymphoma Treatment Market – Treatment Type Pipeline Analysis

### **4. GLOBAL FOLLICULAR LYMPHOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023**

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

### **5. GLOBAL FOLLICULAR LYMPHOMA TREATMENT MARKET, BY TREATMENT TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023**

5.1. Chemotherapy

5.1.1. Alkylating Agents

5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

- 5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 5.1.1.3. Market Opportunity Analysis
- 5.1.2. Nucleoside Analogues
  - 5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 5.1.2.3. Market Opportunity Analysis
- 5.1.3. Anthracycline Derivatives
  - 5.1.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 5.1.3.3. Market Opportunity Analysis
- 5.1.4. Others
  - 5.1.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 5.1.4.3. Market Opportunity Analysis
- 5.2. Radiotherapy
  - 5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 5.2.3. Market Opportunity Analysis
- 5.3. Monoclonal Antibodies
  - 5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 5.3.3. Market Opportunity Analysis
- 5.4. Stem Cell Transplantation
  - 5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 5.4.3. Market Opportunity Analysis

## **6. GLOBAL FOLLICULAR LYMPHOMA TREATMENT MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023**

- 6.1. Oral
  - 6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 6.1.3. Market Opportunity Analysis
- 6.2. Parenteral
  - 6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.2.3. Market Opportunity Analysis

6.3. Others

6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.3.3. Market Opportunity Analysis

## **7. GLOBAL FOLLICULAR LYMPHOMA TREATMENT MARKET FORECAST, BY END-USER, 2012 - 2016 AND FORECAST, 2017 - 2023**

7.1. Hospitals

7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

7.2. Retail Pharmacies

7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

7.3. Oncology Centers

7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.3.3. Market Opportunity Analysis

7.4. Academic Research Institutes

7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.4.3. Market Opportunity Analysis

## **8. GLOBAL FOLLICULAR LYMPHOMA TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023**

8.1. North America

8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.1.3. Market Opportunity Analysis

8.2. Europe

8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.2.3. Market Opportunity Analysis

8.3. Asia-Pacific



- 8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.3.3. Market Opportunity Analysis

#### 8.4. Latin America

- 8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.4.3. Market Opportunity Analysis

#### 8.5. Middle East and Africa

- 8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.5.3. Market Opportunity Analysis

#### 8.6. Global Follicular Lymphoma Treatment Market - Opportunity Analysis Index, By Treatment, By Route of Administration, By End-User, and Region, 2017 – 2023

### **9. NORTH AMERICA FOLLICULAR LYMPHOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

#### 9.1. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

- 9.1.1. Chemotherapy
  - 9.1.1.1. Alkylating Agents
  - 9.1.1.2. Nucleoside Analogues
  - 9.1.1.3. Anthracycline Derivatives
  - 9.1.1.4. Others
- 9.1.2. Radiotherapy
- 9.1.3. Monoclonal Antibodies
- 9.1.4. Stem Cell Transplantation

#### 9.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

- 9.2.1. Oral
- 9.2.2. Parenteral
- 9.2.3. Others

#### 9.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

- 9.3.1. Hospitals
- 9.3.2. Retail Pharmacies
- 9.3.3. Oncology Centers
- 9.3.4. Academic Research Institutes

#### 9.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn)

## Y-o-Y Growth (%) and Market Share (%)

### 9.4.1. U.S.

### 9.4.2. Canada

## 9.5. North America Follicular Lymphoma Treatment Market - Opportunity Analysis Index, By Treatment, By Route of Administration, By End-User and Country, 2017 – 2023

## 9.6. North America Follicular Lymphoma Treatment Market Dynamics – Trends

## **10. EUROPE FOLLICULAR LYMPHOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

### 10.1. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

#### 10.1.1. Chemotherapy

##### 10.1.1.1. Alkylating Agents

##### 10.1.1.2. Nucleoside Analogues

##### 10.1.1.3. Anthracycline Derivatives

##### 10.1.1.4. Others

#### 10.1.2. Radiotherapy

#### 10.1.3. Monoclonal Antibodies

#### 10.1.4. Stem Cell Transplantation

### 10.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

#### 10.2.1. Oral

#### 10.2.2. Parenteral

#### 10.2.3. Others

### 10.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

#### 10.3.1. Hospitals

#### 10.3.2. Retail Pharmacies

#### 10.3.3. Oncology Centers

#### 10.3.4. Academic Research Institutes

### 10.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

#### 10.4.1. Germany

#### 10.4.2. UK

#### 10.4.3. France

#### 10.4.4. Spain

#### 10.4.5. Italy

10.4.6. Russia

10.4.7. Poland

10.4.8. Rest of Europe

10.5. Europe Follicular Lymphoma Treatment Market - Opportunity Analysis Index, By Treatment, By Route of Administration, By End-User and Country, 2017 – 2023

10.6. Europe Follicular Lymphoma Treatment Market Dynamics – Trends

## **11. ASIA-PACIFIC FOLLICULAR LYMPHOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

11.1. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1. Chemotherapy

11.1.1.1. Alkylating Agents

11.1.1.2. Nucleoside Analogues

11.1.1.3. Anthracycline Derivatives

11.1.1.4. Others

11.1.2. Radiotherapy

11.1.3. Monoclonal Antibodies

11.1.4. Stem Cell Transplantation

11.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.2.1. Oral

11.2.2. Parenteral

11.2.3. Others

11.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.3.1. Hospitals

11.3.2. Retail Pharmacies

11.3.3. Oncology Centers

11.3.4. Academic Research Institutes

11.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),

Y-o-Y Growth (%), and Market Share (%)

11.4.1. Japan

11.4.2. China

11.4.3. India

11.4.4. ASEAN

11.4.5. Australia & New Zealand

11.4.6. Rest of Asia-Pacific

11.5. Asia-Pacific Follicular Lymphoma Treatment Market - Opportunity Analysis Index, By Treatment, By Route of Administration, By End-User and Country, 2017 – 2023

11.6. Asia-Pacific Follicular Lymphoma Treatment Market Dynamics – Trends

## **12. LATIN AMERICA FOLLICULAR LYMPHOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

12.1. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.1. Chemotherapy

12.1.1.1. Alkylating Agents

12.1.1.2. Nucleoside Analogues

12.1.1.3. Anthracycline Derivatives

12.1.1.4. Others

12.1.2. Radiotherapy

12.1.3. Monoclonal Antibodies

12.1.4. Stem Cell Transplantation

12.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.2.1. Oral

12.2.2. Parenteral

12.2.3. Others

12.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.3.1. Hospitals

12.3.2. Retail Pharmacies

12.3.3. Oncology Centers

12.3.4. Academic Research Institutes

12.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Argentina

12.4.4. Venezuela

12.4.5. Rest of Latin America

12.5. Latin America Follicular Lymphoma Treatment Market - Opportunity Analysis Index, By Treatment, By Route of Administration, By End-User and Country, 2017 – 2023

12.6. Latin America Follicular Lymphoma Treatment Market Dynamics – Trends

### **13. MIDDLE EAST AND AFRICA FOLLICULAR LYMPHOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

13.1. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.1. Chemotherapy

13.1.1.1. Alkylating Agents

13.1.1.2. Nucleoside Analogues

13.1.1.3. Anthracycline Derivatives

13.1.1.4. Others

13.1.2. Radiotherapy

13.1.3. Monoclonal Antibodies

13.1.4. Stem Cell Transplantation

13.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.2.1. Oral

13.2.2. Parenteral

13.2.3. Others

13.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.3.1. Hospitals

13.3.2. Retail Pharmacies

13.3.3. Oncology Centers

13.3.4. Academic Research Institutes

13.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.4.1. Gulf Cooperation Council (GCC) Countries

13.4.2. Israel

13.4.3. South Africa

13.4.4. Rest of MEA

13.5. MEA Follicular Lymphoma Treatment Market - Opportunity Analysis Index, By Treatment, By Route of Administration, By End-User and Country, 2017 – 2023

13.6. MEA Follicular Lymphoma Treatment Market Dynamics – Trends

### **14. COMPETITION LANDSCAPE**

14.1. Strategic Dashboard of Top Market Players

## 14.2. Company Profiles (Introduction, Financial Analysis, Treatment Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

- 14.2.1. Hoffmann La Roche Ltd. (Switzerland)
- 14.2.2. Novartis AG (Switzerland)
- 14.2.3. GlaxoSmithKline plc (U.K.)
- 14.2.4. Merck & Co. Inc. (U.S.)
- 14.2.5. AbbVie, Inc. (U.S.)
- 14.2.6. Bayer AG (Germany)
- 14.2.7. Epizyme Inc. (U.S.)
- 14.2.8. Bristol Myers Squibb (U.S.)
- 14.2.9. Johnson and Johnson Services Inc. (U.S.)

## 15. RESEARCH METHODOLOGY

## 16. KEY ASSUMPTIONS AND ACRONYMS

## I would like to order

Product name: Follicular Lymphoma Treatment Market, 2012-2023

Product link: <https://marketpublishers.com/r/F6999F1C149EN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F6999F1C149EN.html>